

Novartis

1996 Novartis was formed after merger between Sandoz(1886) & Ciba-Geigy(1970)

Novartis employees worldwide
142 countries, 110,738 persons*



155 countries
 Where Novartis products are used¹



48.7 b \$
 Novartis net sales¹



769m patients
 Treated with Novartis products¹



66m patients
 Reached through Novartis patient care programs¹

#1 in the world's most innovative biotech company⁶
 By U.S business magazine, Fast Company, 2018

No.1 No. of drugs in pipeline from 2018 to 2020^{4,5}
 (among the top 25 global pharmaceutical firms in the world)

160+
 Projects in clinical development based on ongoing trials in phase I ~III and registration⁴

20
 Advanced-platform therapy in clinical trial stage


~90%
 Innovative or initial indication treatment in clinical trial stage

No.1 Diversity and Inclusion index by Refinitiv¹
 (2020, rating for 100 top-performing global pharmaceutical firms)

50%
 Women in employees³

45%
 Women in management¹

Building Therapeutic Area depth in Novartis Innovative Medicines¹¹



References. 1. Novartis annual review 2020 2. Reimagining Medicine Strategy Update. J.P. Morgan Healthcare Conference. January 11, 2021 3. Novartis Website. available at: <https://www.novartis.com/our-company/diversity-inclusion/equity> (as of Feb 17, 2021). 4. Pharma R&D Annual Review 2019 5. Pharma R&D Annual Review 2020 6. Fastcompany. MOST INNOVATIVE COMPANIES 2018 7. Novartis Data on File_Boilerplate 8. Ministry of Food and Drug Safety, 2010-2019 Clinical Trial Approval Status in Korea 9. Ministry of Food and Drug Safety, Statistics relating to patent registrants in Korea, 2020 10. Wifor Institute, The Social Impact of Novartis Innovative Medicines and Sandoz Products in South Korea in 2019. 11. Q4 2020 Results

Novartis Korea

1997 Novartis affiliate in Korea was formed between Sandoz Korea(1986) & Ciba-Geigy Korea(1983)

Novartis employees in Korea
580 associates⁷

No.1
 No. of clinical trial approvals in Korea⁹
 (2011-2020, among the global pharma firms)
 No. of drug patents registered in Korea⁹
 (2021, throughout the pharma firms)

Impact on Korea¹⁰ *2021 data from WifOR research institute¹⁰

Social Impact



KRW 2,247,027,000,000+
 Social Impact of Medicines^{*}

KRW 1,241,790,000+
 Human Capital Impact^{**}

Economic Impact



KRW 417,000,000,000+
 GDP Contribution

Environmental Impact



KRW -49,100,000,000+
 Environmental impact^{***}

^{*}Direct, Indirect and Induced economic impact which is generated by patients becoming healthier as a result of taking Novartis medicine
^{**}Including living wage, occupational safety, and employee development
^{***}Including greenhouse gas (GHG), waste, air pollutants, water consumption, land use, etc.

Creation of SEE impacts worth **KRW 2,060,000,000,000+** across Korea

Innovation

- Contribute to innovation through scientific collaboration and networking
- LOI with the Seoul Metropolitan Government to enhance global capacity of local biotech firms
- MOU with CMC to activate interchange on digital health and data technology
- MOU with Deepnoid for the development of AI solutions related to disease
- MOU with KT to discover and incubate prospective venture companies related to digital healthcare services
- Health X-challenge project to discover and support companies in bio and digital health fields

Patient

- Commit to patients and care givers through various support programs
- 'CHEERYOU' for emotional support for patients with rare diseases and their families
- 'Gahwamomsasung' dedicated to female cancer patients and their families
- '1-EUM' to assist to patients in their return to work and society

Community

- Continue to support the neighbors in need with local communities
- Donating 30,000 masks to support those in need
- Donating 580 million won to Korean Academy of Medical Sciences to support fight against COVID-19
- Novartis Community Partnership Day, an annual volunteer event that has lasted since 1997
- 'Sharing Week' to practice community service for the first week of each year

